Agree with "One drug administered weekly does not have the same financial benefit to a company like Gilead. Gilead will not want the standard of care to be replaced with something cheaper and easier"
Successful Pro-140 monotherapy will kill Gild revenue stream - they can either try to kill the product or buy it before other competitors.
The Jun presentation will be the big event to show the results to all. That will be right moment for deal.
Market Data 
Markets 
AI
